Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
How far is reality of HIV treatment access from optimal? Study looks at preventive impact of antiretroviral therapy where waits are long, stockouts common, and status sometimes secret
Preventive benefit still high, but lessened by access, disclosure obstacles in area where rates are among the highest on earth In KwaZulu-Natal, where rates of HIV […]
Health workers face tuberculosis risks up to three times those of general population, while infection control, worker protections lag
The devastation of the last two years of the Ebola crisis in West Africa was made all the more daunting by a predictable aspect of its […]
The quest for a vaccine that provides lasting protection against malaria took another step forward today with the release of study results showing a candidate made […]
“Zika is a test to see if we’ve learned anything from Ebola” — Emergency funding not enough to deal with emerging infections, panelists say
The 1.9 billion dollars the Obama Administration has requested to respond to the Zika virus is not enough, according to Amy Pope. It’s not enough to […]